A Pilot Study to Develop Predictive Biomarkers for the Response to Immunotherapy in Lung Cancer
| Status: | Recruiting |
|---|---|
| Conditions: | Lung Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 9/29/2018 |
| Start Date: | November 22, 2016 |
| Contact: | Charu Aggarwal, MD |
| Email: | PennCancerTrials@emergingmed.com |
| Phone: | 855-216-0098 |
Several immune checkpoint inhibitors targeting the PD-1 pathway have been developed with
clinical trials showing an approximately 20% durable response in unselected patients with
advanced non-small cell lung cancer (NSCLC). At the moment, no clear biomarker exists to
accurately predict anti-PD1/PDL1 tumor responsiveness. The goal of this study is to broadly
discover and evaluate the utility of blood based biomarkers for use in measuring and
predicting response to immunotherapy in patients with lung cancer.
clinical trials showing an approximately 20% durable response in unselected patients with
advanced non-small cell lung cancer (NSCLC). At the moment, no clear biomarker exists to
accurately predict anti-PD1/PDL1 tumor responsiveness. The goal of this study is to broadly
discover and evaluate the utility of blood based biomarkers for use in measuring and
predicting response to immunotherapy in patients with lung cancer.
Inclusion Criteria:
- Advanced Metastatic NSCLC
- Scheduled to initiate an immune checkpoint inhibitor
- Age >= 18 years
- Able to provide informed consent
Exclusion Criteria:
- Other, unrelated, concomitant active, invasive malignancy
We found this trial at
1
site
3400 Civic Center Blvd
Philadelphia, Pennsylvania 19104
Philadelphia, Pennsylvania 19104
(215) 662-6065
Phone: 855-216-0098
Abramson Cancer Center of the University of Pennsylvania The Abramson Cancer Center of the University...
Click here to add this to my saved trials
